At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 336 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
This is a product surveillance registry run by Medtronic. It collects information from patients who have, or are due to receive, an eligible Medtronic product, covering a wide range of conditions such as heart rhythm problems, neurological disorders and coronary artery disease. The aim is to gather ongoing information about how these products perform.
Who can take part
- You (or your legal representative) give written permission or consent, following the rules of your hospital and country
- You have, or are due to receive or be treated with, an eligible Medtronic product
- You are within the enrolment window for starting your treatment, or you meet the rules for joining after treatment has started
Who may not be able to
- You cannot be reached for follow-up checks, now or in the future
- Local law says you cannot take part
- You are already in, or plan to join, another study of a drug or device that could affect the results
What taking part involves
- • Your treatment itself is not changed by the registry — it collects information about the Medtronic product you are receiving. Details of what is monitored are not stated — ask the trial team.
Time commitment: Not stated — ask the trial team about how many visits there are, how long it lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- Not specified
- Who
- All
- Number of participants
- 100,000
- Started
- 2012-01
- Last checked
- 2025-12
Plain English Summary
What is this study?
- • Testing a new treatment for cardiac rhythm disorders
- • Clinical study - 100,000 participants
- • The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products
Who can take part?
- • Adults
- • Diagnosed with cardiac rhythm disorders
Where?
- • Barnstaple
- • Birmingham
- • Blackpool
- • Bristol
- • +13 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: Not specified
- Who can join: All genders
What the study is looking for
- ✓Patient or legally authorized representative provides written authorization and/or consent per institution and...
- ✓Patient has or is intended to receive or be treated with an eligible Medtronic product
- ✓Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment
Who cannot take part
- ✗Patient who is, or will be, inaccessible for follow-up
- ✗Patient with exclusion criteria required by local law
- ✗Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
See the full criteria
Where Is This Study? (17 UK sites)
Barnstaple, United Kingdom
Birmingham, United Kingdom
Blackpool, United Kingdom
Bristol, United Kingdom
Chelmsford, United Kingdom
Glasgow, United Kingdom
Harrow, United Kingdom
Leeds, United Kingdom
Leicester, United Kingdom
Liverpool, United Kingdom
London, United Kingdom
Manchester, United Kingdom
Middlesbrough, United Kingdom
Newcastle upon Tyne, United Kingdom
Northampton, United Kingdom
Sheffield, United Kingdom
Southampton, United Kingdom
How to Get in Touch
Medtronic Product Surveillance Registry
Sponsor contactCONTACT